ArticleCanadian liver journal2026
Steatotic liver disease in autoimmune liver disease: Prevalence and clinical impact in a Southeast Asian cohort.
Article in Canadian liver journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Steatotic liver disease (SLD) is increasingly common in patients with primary biliary cholangitis (PBC) and autoimmune hepatitis (AIH). We sought to determine the prevalence and clinical impact of SLD among Southeast Asian patients with PBC, AIH, and AIH/PBC overlap syndrome. Methods: We included all patients diagnosed with PBC, AIH and AIH/PBC overlap syndrome between 2000 and 2024. SLD was defined based on either radiological or histological evidence of hepatic steatosis. The primary outcomes were all-cause mortality, treatment response, liver-related events (LRE), and major adverse cardiovascular events (MACE). Results: Among 273 patients (PBC: 184, AIH: 69, AIH/PBC overlap syndrome: 20), one third had concomitant SLD. Patients with PBC/SLD were more likely to have a higher BMI (24.6 versus 22.6 kg/m Conclusions: Concomitant SLD does not influence treatment response, liver-related events, or cardiovascular outcomes in patients with autoimmune liver disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.